Novel EGFR inhibitors attenuate cardiac hypertrophy induced by angiotensin II

Journal of Cellular and Molecular Medicine

Volumn 20, Issue 3, 2016, Pages 482-494

  Peng, Kesong ^a   Tian, Xinqiao ^b   Qian, Yuanyuan ^a   Skibba, Melissa ^a   Zou, Chunpeng ^b   Liu, Zhiguo ^a   Wang, Jingying ^a   Xu, Zheng ^a   Li, Xiaokun ^a   Liang, Guang ^a  

^a WENZHOU MEDICAL UNIVERSITY   (China)

^b THE SECOND AFFILIATED HOSPITAL AND YUYING CHILDREN S HOSPITAL OF WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Angiotensin II; C Src; Cardiac hypertrophy; Epidermal growth factor receptor; Small molecule inhibitor

Indexed keywords

4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; 542; 543; ANGIOTENSIN II; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; UNCLASSIFIED DRUG; CARDIOTONIC AGENT; EGFR PROTEIN, MOUSE; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; QUINAZOLINE DERIVATIVE; TYRPHOSTIN;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHEMICAL STRUCTURE; CONTROLLED STUDY; ECHOCARDIOGRAPHY; GENE SILENCING; HEART VENTRICLE HYPERTROPHY; HISTOPATHOLOGY; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RISK FACTOR; SIGNAL TRANSDUCTION; TRANSIENT TRANSFECTION; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CARDIAC MUSCLE CELL; CARDIOMEGALY; CELL LINE; CHEMICALLY INDUCED; DRUG EFFECTS; GENETICS; METABOLISM; PHYSIOLOGY; PRECLINICAL STUDY; RAT;

ANGIOTENSIN II; ANIMALS; CARDIOMEGALY; CARDIOTONIC AGENTS; CELL LINE; DRUG EVALUATION, PRECLINICAL; EPIDERMAL GROWTH FACTOR; GENE KNOCKDOWN TECHNIQUES; MICE, INBRED C57BL; MYOCYTES, CARDIAC; QUINAZOLINES; RATS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TYRPHOSTINS;

EID: 84958612091     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/jcmm.12763     Document Type: Article

References (38)

1. Kolo PM, Jibrin YB, Sanya EO, et al. Hypertension-related admissions and outcome in a tertiary hospital in northeast Nigeria. Int J Hypertens. 2012; 2012: 960546.
2. Frey N, Olson EN. Cardiac hypertrophy: the good, the bad, and the ugly. Annu Rev Physiol. 2003; 65: 45-79.
3. Zablocki D, Sadoshima J. Angiotensin II and oxidative stress in the failing heart. Antioxid Redox Signal. 2013; 19: 1095-109.
4. Wang RH, He JP, Su ML, et al. The orphan receptor TR3 participates in angiotensin II-induced cardiac hypertrophy by controlling mTOR signalling. EMBO Mol Med. 2013; 5: 137-48.
5. Xie X, Wang Y, Zhang S, et al. Chinese red yeast rice attenuates the development of angiotensin II-induced abdominal aortic aneurysm and atherosclerosis. J Nutr Biochem. 2012; 23: 549-56.
6. Zhang W, Chen DQ, Qi F, et al. Inhibition of calcium-calmodulin-dependent kinase II suppresses cardiac fibroblast proliferation and extracellular matrix secretion. J Cardiovasc Pharmacol. 2010; 55: 96-105.
7. Porrello ER, Meeker WF, Thomas WG, et al. Glucocorticoids suppress growth in neonatal cardiomyocytes co-expressing AT(2) and AT(1) angiotensin receptors. Neonatology. 2010; 97: 257-65.
8. Kim S, Ohta K, Hamaguchi A, et al. Angiotensin II induces cardiac phenotypic modulation and remodeling in vivo in rats. Hypertension. 1995; 25: 1252-9.
9. Zhai P, Galeotti J, Liu J, et al. An angiotensin II type 1 receptor mutant lacking epidermal growth factor receptor transactivation does not induce angiotensin II-mediated cardiac hypertrophy. Circ Res. 2006; 99: 528-36.
10. Paradis P, Dali-Youcef N, Paradis FW, et al. Overexpression of angiotensin II type I receptor in cardiomyocytes induces cardiac hypertrophy and remodeling. Proc Natl Acad Sci USA. 2000; 97: 931-6.
11. Burgess AW, Cho H-S, Eigenbrot C, et al. An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. Mol Cell. 2003; 12: 541-52.
12. Lemmon MA, Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell. 2010; 141: 1117-34.
13. Prada PO, Ropelle ER, Mourao RH, et al. EGFR tyrosine kinase inhibitor (PD153035) improves glucose tolerance and insulin action in high-fat diet-fed mice. Diabetes. 2009; 58: 2910-9.
14. Schreier B, Rabe S, Schneider B, et al. Loss of epidermal growth factor receptor in vascular smooth muscle cells and cardiomyocytes causes arterial hypotension and cardiac hypertrophy. Hypertension. 2013; 61: 333-40.
15. Gao P, Wang XM, Qian DH, et al. Induction of oxidative stress by oxidized LDL via meprinalpha-activated epidermal growth factor receptor in macrophages. Cardiovasc Res. 2013; 97: 533-43.
16. Choi SK, Galan M, Partyka M, et al. Chronic inhibition of epidermal growth factor receptor tyrosine kinase and extracellular signal-regulated kinases 1 and 2 (ERK1/2) augments vascular response to limb ischemia in type 2 diabetic mice. Am J Pathol. 2012; 180: 410-8.
17. Wang X, Huong S-M, Chiu ML, et al. Epidermal growth factor receptor is a cellular receptor for human cytomegalovirus. Nature. 2003; 424: 456-61.
18. Zhou G, Li X, Hein DW, et al. Metallothionein suppresses angiotensin II-induced nicotinamide adenine dinucleotide phosphate oxidase activation, nitrosative stress, apoptosis, and pathological remodeling in the diabetic heart. J Am Coll Cardiol. 2008; 52: 655-66.
19. Ai W, Zhang Y, Tang QZ, et al. Silibinin attenuates cardiac hypertrophy and fibrosis through blocking EGFR-dependent signaling. J Cell Biochem. 2010; 110: 1111-22.
20. Sandoval YH, Li Y, Anand-Srivastava MB. Transactivation of epidermal growth factor receptor by enhanced levels of endogenous angiotensin II contributes to the overexpression of Gialpha proteins in vascular smooth muscle cells from SHR. Cell Signal. 2011; 23: 1716-26.
21. Grimminger F, Schermuly RT, Ghofrani HA. Targeting non-malignant disorders with tyrosine kinase inhibitors. Nat Rev Drug Discov. 2010; 9: 956-70.
22. Hemminki K, Rawal R, Bermejo JL. Mammographic screening is dramatically changing age-incidence data for breast cancer. J Clin Oncol. 2004; 22: 4652-3.
23. Costa DB, Huberman MS. Improvement of type 2 diabetes in a lung cancer patient treated with Erlotinib. Diabetes Care. 2006; 29: 1711.
24. Templeton A, Brandle M, Cerny T, et al. Remission of diabetes while on sunitinib treatment for renal cell carcinoma. Ann Oncol. 2008; 19: 824-5.
25. Veneri D, Franchini M, Bonora E. Imatinib and regression of type 2 diabetes. N Engl J Med. 2005; 352: 1049-50.
26. Schreier B, Gekle M, Grossmann C. Role of epidermal growth factor receptor in vascular structure and function. Curr Opin Nephrol Hypertens. 2014; 23: 113-21.
27. Chen J, Chen JK, Nagai K, et al. EGFR signaling promotes TGFbeta-dependent renal fibrosis. J Am Soc Nephrol. 2012; 23: 215-24.
28. Kagiyama S, Eguchi S, Frank GD, et al. Angiotensin II-induced cardiac hypertrophy and hypertension are attenuated by epidermal growth factor receptor antisense. Circulation. 2002; 106: 909-12.
29. Heineke J, Molkentin JD. Regulation of cardiac hypertrophy by intracellular signalling pathways. Nat Rev Mol Cell Biol. 2006; 7: 589-600.
30. Yin G, Yan C, Berk BC. Angiotensin II signaling pathways mediated by tyrosine kinases. Int J Biochem Cell Biol. 2003; 35: 780-3.
31. Chaanine AH, Hajjar RJ. AKT signalling in the failing heart. Eur J Heart Fail. 2011; 13: 825-9.
32. Bueno OF, Molkentin JD. Involvement of extracellular signal-regulated kinases 1/2 in cardiac hypertrophy and cell death. Circ Res. 2002; 91: 776-81.
33. Duquesnes N, Vincent F, Morel E, et al. The EGF receptor activates ERK but not JNK Ras-dependently in basal conditions but ERK and JNK activation pathways are predominantly Ras-independent during cardiomyocyte stretch. Int J Biochem Cell Biol. 2009; 41: 1173-81.
34. Skouta R, Dixon SJ, Wang J, et al. Ferrostatins inhibit oxidative lipid damage and cell death in diverse disease models. J Am Chem Soc. 2014; 136: 4551-6.
35. Chiu CZ, Wang BW, Shyu KG. Angiotensin II and the JNK pathway mediate urotensin II expression in response to hypoxia in rat cardiomyocytes. J Endocrinol. 2014; 220: 233-46.
36. Manabe I, Shindo T, Nagai R. Gene expression in fibroblasts and fibrosis: involvement in cardiac hypertrophy. Circ Res. 2002; 91: 1103-13.
37. Jacoby JJ, Kalinowski A, Liu MG, et al. Cardiomyocyte-restricted knockout of STAT3 results in higher sensitivity to inflammation, cardiac fibrosis, and heart failure with advanced age. Proc Natl Acad Sci USA. 2003; 100: 12929-34.
38. Hsieh HL, Lin CC, Chan HJ, et al. c-Src-dependent EGF receptor transactivation contributes to ET-1-induced COX-2 expression in brain microvascular endothelial cells. J Neuroinflammation. 2012; 9: 152.